Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bacterial Membrane Proteins Generate Broad-Spectrum Immune Protection

By LabMedica International staff writers
Posted on 09 Jan 2012
A new generation of vaccines against bacterial pathogens may be based on affinity to common cross-genus or cross-species membrane proteins rather than to serotype specific polysaccharide antigens.

Investigators at the University of Pittsburgh School of Medicine (PA, USA) used the bacterium Klebsiella pneumoniae to establish a model respiratory disease in a population of laboratory mice. More...
When the animals were exposed to heat-killed K. pneumoniae, they eventually developed an antibody response that protected them from subsequent challenge with living organisms of the same strain. However, these antibodies provided little protection from infection by different serotypes of the bacteria.

Results published in the December 23, 2011, issue of the journal Immunity, revealed that in addition to the antibody response, which was directed at capsular polysaccharides, the mice also increased production of T helper 17 cells (Th17) in response to conserved outer membrane proteins that conferred protection against several serotypes of K. pneumoniae.

Th17 cells are a subset of T helper cells producing interleukin 17 (IL-17) discovered in 2007. Initially, Th17 cells were broadly implicated in autoimmune disease, and auto-specific Th17 cells were shown to be highly pathologic. A more natural role for Th17 cells was suggested by studies that demonstrated preferential induction of IL-17 in cases of host infection with various bacterial and fungal species. Th17 cells primarily produce two main members of the IL-17 family, IL-17A and IL-17F, which are involved in the recruitment, activation, and migration of neutrophils. Th17 cells respond to protein complexes in the bacterial cell membrane. Those proteins, which are integral to the structure of the cell membrane, tend to be similar across bacterial strains, unlike the capsular polysaccharides, which are variable.

Senior author Dr. Jay K. Kolls, professor of pediatrics and immunology at the University of Pittsburgh School of Medicine, said, "Some current vaccines require generating a response to a number of these capsular sugars for effective immunization. An approach that harnesses the stability of the Th17 cell response to common proteins has the potential to simplify vaccination and provide a broader spectrum of coverage. This strategy may be particularly useful against bacteria that have diverse capsular sugars or multidrug resistant organisms."

Related Links:
University of Pittsburgh School of Medicine


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.